Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.38 |
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MPI | P34949 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6508732 | 0.85 | SRC (0.44) | SRCERN1KDM4EALDH1A1TDP1 | |
| SCHEMBL7284734 | 0.84 | SRC (0.52) | SRCERN1KDM4EALDH1A1TDP1 | |
| SCHEMBL7283876 | 0.83 | SRC (0.50) | SRCERN1KDM4EALDH1A1TDP1 | |
| SCHEMBL30251825 | 0.82 | SRC (0.47) | SRCERN1KDM4EALDH1A1TDP1 | |
| SCHEMBL22897454 | 0.78 | SRC (0.44) | SRCERN1KDM4EALDH1A1TDP1 | |
| SCHEMBL7679676 | 0.78 | SRC (0.46) | SRCKDM4EALDH1A1TDP1LMNA | |
| SCHEMBL7290764 | 0.76 | SRC (0.47) | SRCERN1KDM4EALDH1A1TDP1 | |
| SCHEMBL28464657 | 0.75 | ERN1 (0.44) | SRCERN1KDM4EALDH1A1LMNA | |
| SCHEMBL9146840 | 0.75 | SRC (0.44) | SRCERN1KDM4EALDH1A1TDP1 | |
| SCHEMBL6736649 | 0.74 | SRC (0.49) | SRCERN1KDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436939-B2 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS INCLUDING SLEEP/WAKE DISORDERS, DEMENTIA, ALZHEIMER'S DISEASE, EPILEPSY, NARCOLEPSY, EATING DISORDERS, MOTION SICKNESS, VERTIGO | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-08-20 | — | — | US | disclosed |
| US-20010044439-A1 | Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as H3 antagonists | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2001-11-22 | — | — | US | disclosed |
| WO-2001074810-A2 | METHOD FOR USING 2-ARYLOXYALKYLAMINOBENZOXAZOLES AND 2-ARYLOXYALKYLAMINOBENZOTHIAZOLES AS H3 ANTAGONISTS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044439-A1 | Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as H3 antagonists | HRH3, HRH4, HRH2 | SRC 1547/4885ERN1 4643/4885KDM4E 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.